Biotech could be best pick ‘in a world where there’s no value’: Investor

Biotech stocks this week hit their highest levels since January, and some analysts say the stocks have room to run.

The iShares Nasdaq biotechnology index (IBB), which tracks the performance of biotech and pharmaceutical companies listed on the Nasdaq, hit its highest levels in seven months on Thursday.

"We believe that you're going to see consistent revenue growth, as well as improvement within operating margins over the next three to five years," said Chad Morganlander, portfolio manager with Stifel Nicolaus.

"In a world where there's no value, this one, certainly, I would serve up as a value play," Morganlander said Thursday on CNBC's "Power Lunch."

Morganlander added one strong player in the space is Amgen, the multinational biopharmaceutical company that comprises 8.32 percent of the IBB; this is the second-largest weighted company in the index, after Celgene.

Amgen, said Morganlander, is a "dividend grower," with a yield of 2.3 percent, and a growth rate of between 15 and 20 percent. He places a price target of about $200.

The IBB hit an all-time high a little over a year ago. Since then, the group has come down quite a bit, plummeting in the first few weeks of 2016.

This bounce the ETF is enjoying since those low levels in January has made several analysts more bullish on the sector.

"We are seeing something occur very different on the desk here. We're seeing people versus selling every rally, or shorting every rally, coming in now and buying every dip," said David Seaburg, Cowen's head of equity sales trading, on "Power Lunch."

"We're seeing a big sentiment shift in general; people getting very comfortable, and that's mainly right after a lot of big-cap names have reported good quarters, decent guides," said Seaburg.

It's not all tulips and roses for biotech stocks, however. Bristol-Myers shares tanked Friday on news of a failed clinical trial for a key cancer drug.

Videos

Trades to Watch

Trader Bios

About

Trading Nation is a multimedia financial news program that shows investors and traders how to use the news of the day to their advantage. This is where experts from across the financial world – including macro strategists, technical analysts, stock-pickers, and traders who specialize in options, currencies, and fixed income – come together to find the best ways to capitalize on recent developments in the market. Trading Nation: Where headlines become opportunities.

Michael Santoli

Michael Santoli joined CNBC in October 2015 as a Senior Markets Commentator, based at the network's Global Headquarters in Englewood Cliffs, N.J.  Santoli brings his extensive markets expertise to CNBC's Business Day programming, with a regular appearance on CNBC's “Closing Bell (M-F, 3PM-5PM ET).   In addition, he contributes to CNBCand CNBC PRO, writing regular articles and creating original digital videos.

Previously, Santoli was a Senior Columnist at Yahoo Finance, where he wrote analysis and commentary on the stock market, corporate news and the economy. He also appeared on Yahoo Finance video programs, where he offered insights on the most important business stories of the day, and was a regular contributor to CNBC and other networks.

Follow Michael Santoli on Twitter @michaelsantoli

Read more

Connect